Anita Shah, DO
Pulmonary Disease · Chicago, ILNPI 1760534192
Payments from drug & device makers
Across 194 payments — averaging $65.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- AstraZeneca$782
- GSK$772
- Inari Medical, Inc.$524
- Boehringer Ingelheim$229
- Sanofi$216
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$1,0008%
- Travel & lodging$1,32810%
- Food & beverage$4,34134%
- Education$6,05348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $8,773 |
| AstraZeneca | 28 | $782 |
| GSK | 53 | $772 |
| Inari Medical, Inc. | 3 | $524 |
| Boehringer Ingelheim | 11 | $229 |
| Sanofi | 10 | $216 |
| Electromed, Inc. | 27 | $172 |
| Regeneron Healthcare Solutions, Inc. | 5 | $170 |
| Livanova USA, Inc. | 2 | $167 |
| Philips North America LLC | 4 | $108 |
| Inspire Medical Systems, Inc. | 3 | $81 |
| Mylan Specialty L.p. | 3 | $70 |
| Merck | 3 | $66 |
| Circassia Inc. | 2 | $64 |
| Genentech USA, Inc. | 2 | $64 |
| Baxter Healthcare | 2 | $57 |
| Amgen | 3 | $54 |
| Grifols USA, LLC | 2 | $50 |
| Siemens Medical Solutions USA, Inc. | 2 | $42 |
| Inogen, Inc. | 1 | $40 |
| GE HealthCare | 1 | $39 |
| Johnson & Johnson | 2 | $36 |
| Shionogi Inc | 2 | $33 |
| Pfizer | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Ambu Inc. | 1 | $24 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Chiesi USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$6,000
- Da Vinci Surgical System$1,404
- DA VINCI SP$1,000
- FLOWTRIEVER CATHETER, S$524
- CT THROMBECTOMY SYSTEM KIT$524
- FASENRA$257
- SYMBICORT$132
- FARXIGA$125
- BREZTRI$125
- LifeSPARC$104
How this compares
$12,722 in reported general payments places this provider in the 75th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 224 | $326,333 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $58,695 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $38,692 |
| Spiriva RespimatTiotropium Bromide | 31 | $32,125 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $21,592 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $18,076 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $15,056 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $5,107 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,145 |
| Ventolin HfaAlbuterol Sulfate | 36 | $2,745 |
| Zafirlukast | 12 | $818 |
| Azelastine Hcl | 13 | $641 |
| Montelukast Sodium | 39 | $511 |
| Fluticasone Propionate | 17 | $245 |
| Prednisone | 39 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $772 | $445,313374 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $229 | $47,18147 claims |
| AstraZenecaBreztri Aerosphere | $782 | $18,07623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Jane Dematte DamicoChicago$811K
- Septimiu MurguChicago$804K
- Richard WunderinkChicago$725K
- Dustin FraidenburgChicago$678K
- Ayodeji AdegunsoyeChicago$630K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.